TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 14 mg
Description: 1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 14 mg
Description: 1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: 1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 28 mg
Description: 1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study: NCT02036580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tralokinumab cohort 1
Description: Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tralokinumab cohort 2
Description: Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02149355

Intervention type: OTHER
Intervention: teeth molding
Description: teeth molding in patients suffering from congenital fourth nerve palsy

Intervention type: OTHER
Intervention: teeth molding
Description: teeth molding in patients suffering from congenital fourth nerve palsy
Study: NCT00452075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study: NCT03172299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: False injection
Description: A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
Study: NCT01693497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (German Adaptation)
Description: This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
Study: NCT04812782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter supplementation
Description: We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
Study: NCT02959294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV deployment AD-cSVF
Description: Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
Study: NCT03141125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physalis angulata ethanol extract
Description: Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active component at the same dosage of 3x250 mg/day given orally for 3 months
Study: NCT02478632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects do not receive study medication in this study 202094
Description: Participants do not receive study medication in this study 202094.
Study: NCT00287001

Intervention type: DEVICE
Group type: OTHER
Intervention: Cold air cooling
Study: NCT02108756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-pantoprazole sodium
Description: 2 injection L-pantoprazole sodium (40mg), Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panmeilu
Description: An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
Study: NCT01602601

Intervention type: DRUG
Intervention: Idursulfase
Description: recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.

Intervention type: DRUG
Intervention: GSK2788723
Description: GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
Study: NCT02136004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closer VSS
Description: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
Study: NCT04115774

Intervention type: DRUG
Intervention: bisphosphonates
Description: Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
Study: NCT01258556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with L. rhamnosus fiti
Description: 200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt not supplemented with a probiotic strain.
Description: 200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
Study: NCT01539070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating and physical activity counseling
Description: The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity.
Study: NCT01281384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Imaging
Study: NCT04053972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral lenvatinib after hepatectomy
Study: NCT04875455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation
Description: In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
Study: NCT02998671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CJM112

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02038946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02272036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy is performed in both study arm as standard examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy is performed in both study arm as standard examination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone
Description: SMS received by mobile phone
Study: NCT03098433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT01667133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib - Phase 1
Description: 30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib - Phase 2
Description: Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
Study: NCT04397367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg twice a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg once a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 2.5 mg once a day combined with Corticosteroids
Description: Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
Study: NCT04173286

Intervention type: PROCEDURE
Intervention: antibiotherapy
Description: \< 7 days

Intervention type: PROCEDURE
Intervention: antibiotherapy
Description: \< 7 days
Study: NCT01331746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD515
Description: 20 mg oromucosal-oral administration qds for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: qds for 7 days
Study: NCT02720523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study: NCT01802593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZATHIOPRINE or METHOTREXATE
Description: Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZATHIOPRINE or METHOTREXATE
Description: Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks
Study: NCT00791050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allon Thermowrap. MTRE Advanced Technologies Ltd.
Description: Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery.
Study: NCT02191280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®, high dose
Study: NCT04154423

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glow! Group Prenatal Care
Description: Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Prenatal Care with CPSP
Description: Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
Study: NCT02929199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All ceramic crown
Description: Pressed E-Max coping veneered with E-max veneering system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid crown
Description: pressed Bio HPP veneered with Visio-Lign Veneering system
Study: NCT02191280

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02822651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
Study: NCT00292071

Intervention type: DRUG
Group type: OTHER
Intervention: caspofungin acetate
Description: (50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.

Intervention type: DRUG
Group type: OTHER
Intervention: caspofungin acetate
Description: (50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
Study: NCT00289289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Pacing Features
Description: Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Pacing Features
Description: Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
Study: NCT03711370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear Bottle
Description: These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
Study: NCT02822651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered questionnaire
Description: Patients will fill a self-administered questionnaire the day of inclusion
Study: NCT01930240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Description: 1-MNA Chloride
Study: NCT03711370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opaque Bottle
Description: These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
Study: NCT01270880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor STA-9090
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectrophotometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study: NCT01541735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 40 mg dose.
Study: NCT00918606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: LIPO-102
Study: NCT04810364

Intervention type: RADIATION
Intervention: Quantitative coronary angiography, intravascular imaging with percutaneous intervention
Description: Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
Study: NCT00182078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
Study: NCT01679678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PolyHeal 2
Description: PolyHeal is a sterile medical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyheal
Description: PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
Study: NCT01473199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioPoly RS Partial Resurfacing Knee Implant
Description: A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
Study: NCT00229697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib